Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
Status:
Not yet recruiting
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
This study is for patients who have bladder cancer that invades into the muscle wall of the
bladder. The standard treatment for patients with muscle invasive bladder cancer is to give 4
cycles of chemotherapy with the drugs cisplatin and gemcitabine, then to do an operation to
remove the bladder (cystectomy).
In this study, the investigators will test participants' bladder cancer to see if their
bladder cancer has a receptor for testosterone inside the bladder cancer cells. If it has the
testosterone receptor participants will receive a medication called Degarelix that lowers
testosterone levels in the blood. Degarelix will be given during the period that participants
are receiving the standard of care chemotherapy drugs gemcitabine and cisplatin.
The purpose of this study is to evaluate the effects, good and bad, of adding Degarelix to
standard chemotherapy for patients with bladder cancer that have the testosterone receptor.
Phase:
Phase 1
Details
Lead Sponsor:
Brown University
Collaborators:
Cures Within Reach Legorreta Cancer Center at Brown University Lifespan